ArticleClinical rheumatology2026
A Lipid- and Inflammation-Related Metabolite Risk Score Predicts Incident Gout Among Individuals With Hyperuricemia: A Prospective Cohort Study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough hyperuricemia (HUA) is required for gout development, only a fraction of individuals with elevated serum urate progress to the disease. Metabolomic profiling may help uncover biological mechanisms and improve prediction of gout onset.
methodsWe conducted a prospective metabolomics analysis among 32,563 HUA individuals in the UK Biobank. Baseline plasma metabolites were measured, and differences between individuals who developed gout (n = 2,856) and those who did not were identified. Cox proportional hazards models with false discovery rate correction assessed metabolite-gout associations. Significant metabolites and clinical factors were selected using LASSO-Cox and stepwise regression to construct a gout risk score (GRS). Model performance was evaluated in a test set using survival analysis and time-dependent receiver operating characteristic (ROC) curves. Sensitivity and subgroup analyses, along with validation in an independent validation set and transcriptomic profiling, tested the robustness and biological relevance of results.
resultsThe final GRS incorporated six metabolites and three clinical variables. It was strongly associated with incident gout (HR = 2.94, 95% CI 2.66-3.23), and individuals in the top quartile had markedly higher risk. The model showed stable predictive ability, with time-dependent AUCs of 0.81-0.79 in the training set and 0.85-0.79 in the test set across 1-10 years. Further validation of the GRS in the independent validation set confirmed the performance. Transcriptomic analyses independently revealed enrichment of inflammatory and lipid-metabolic pathways, consistent with the metabolites included in the GRS.
conclusionsWe developed a lipid- and inflammation-related GRS that effectively predicts gout onset among HUA individuals, offering a useful tool for early risk stratification and targeted prevention. Key Points • An NMR-based metabolomics analysis identified several lipid- and inflammation-related metabolites strongly associated with incident gout among individuals with hyperuricemia. • A gout risk score integrating six metabolites and three clinical factors demonstrated robust and stable predictive performance over up to 10 years of follow-up. • Individuals in the highest quartile of the metabolite-based risk score had substantially elevated gout risk, improving early identification of high-risk subgroups. • Transcriptomic profiling revealed enrichment of inflammatory and lipid-metabolic pathways, supporting the biological plausibility of the findings.
Indexed as
Identifiers
42101755What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.